Q-omics provides the consensus-scored LGALS7B profile across patient tissues and cancer cell-line models. LGALS7B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LGALS7B is differentially expressed in 12, with the highest sampling consensus in UCEC. Additionally, LGALS7B RNA expression shows 11,199 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight UVM, UCEC, and ESCA as cancer lineages where LGALS7B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LGALS7B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LGALS7B survival associations across molecular data types. LGALS7B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LGALS7B RNA expression–survival associations across cancer types. High LGALS7B expression shows unfavorable associations in UVM, UCEC, BLCA and SKCM, but favorable associations in THCA and ESCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for LGALS7B RNA expression.
This table summarizes LGALS7B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for LGALS7B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LGALS7B shows lower tumor expression in KICH and BRCA and higher tumor expression in UCEC, LUSC, LUAD and COAD. The UCEC box plot shows higher LGALS7B RNA expression in tumor versus normal tissue (log2 FC = +1.624, t-test p < 0.001).
This table shows molecular features associated with LGALS7B in patient tissues and cancer cell lines. In patient samples, LGALS7B shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, LGALS7B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LUNG_NSCLC_LUSC.
